BioCentury
ARTICLE | Management Tracks

New CEOs at Anjarium, Cambridge Epigenetix

Plus Sema4’s CFO to step down, and updates from Marengo, Avilar, City of Hope and more

June 16, 2022 12:01 AM UTC

Non-viral gene therapy company Anjarium Biosciences AG named Stephen Yoo CEO. Yoo was CMO and head of R&D at Third Harmonic Bio Inc., before which he was CMO at RegenxBio Inc. (NASDAQ:RGNX).

Peter Fromen will become CEO at Cambridge Epigenetix Ltd. on July 18, replacing acting CEO Gail Marcus, who will continue as chairman. Fromen joins the DNA-sequencing company from Pacific Biosciences of California Inc. (NASDAQ:PACB), where he was the chief commercial officer...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article